NCT06784726 2026-03-13
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
Phase 2 Recruiting
Clinical Trials
42 trialsNCT07340853 2026-03-10
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT05003895 2026-03-03
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06481228 2026-03-02
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT06481241 2026-03-02
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT04512716 2026-02-17
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT07052305 2026-02-12
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Washington University School of Medicine
Phase 1 Recruiting
NCT05800405 2026-02-04
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT04180059 2026-01-26
CTL-DP 01
Nantes University Hospital
Phase 1 Recruiting
NCT04995003 2026-01-22
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Baylor College of Medicine
Phase 1 Recruiting
NCT04545762 2026-01-14
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 1 Recruiting
NCT06104592 2026-01-08
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06482905 2026-01-06
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Tcelltech Inc.
Phase 1 Recruiting
NCT05260957 2025-12-31
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
University of Miami
Phase 2 Recruiting
NCT06218602 2025-12-16
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07280494 2025-12-12
S101MRD
Peking University People's Hospital
Phase 1 Recruiting
NCT06649227 2025-12-05
CARLA-M19
University Hospital, Lille
Phase 1 Recruiting
NCT07053670 2025-11-17
CT1190B
Tongji Hospital
Phase 1 Recruiting
NCT07231081 2025-11-17
Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors
Tcelltech Inc.
Phase 1 Recruiting
NCT07103668 2025-10-23
A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
Suzhou Immunofoco Biotechnology Co., Ltd
Phase 3 Recruiting
NCT06854159 2025-09-29
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
University of California, Davis
Phase 2 Recruiting
NCT07097207 2025-07-31
CAR-T
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT02917083 2025-07-25
RELY-30
Baylor College of Medicine
Phase 1 Recruiting
NCT05225363 2025-07-01
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06815029 2025-06-26
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
Phase 1 Recruiting
NCT06822868 2025-02-12
CT1190B
Beijing GoBroad Hospital
Phase 1 Recruiting
NCT06796517 2025-01-28
Immunotherapy in Lymphoma
Seoul St. Mary's Hospital
Recruiting
NCT06752785 2024-12-31
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Guangzhou Women and Children's Medical Center
Phase 1 Recruiting
NCT06724835 2024-12-09
Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)
Shenzhen Celconta Life Science Co., Ltd.
Phase 1 Recruiting
NCT06698484 2024-11-21
CAR-T for NHL
National University of Malaysia
Phase 2 Recruiting
NCT05587543 2024-11-12
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
Fudan University
Phase EARLY_PHASE1 Recruiting
NCT06642025 2024-10-15
EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia
The Second Hospital of Anhui Medical University
Phase EARLY_PHASE1 Recruiting
NCT05779917 2024-06-25
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
Phase 1 Recruiting
NCT06429150 2024-06-10
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT06439173 2024-06-03
Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment
Instituto de Investigación Biomédica de Salamanca
Recruiting
NCT05268172 2024-05-16
IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites
Affiliated Hospital of Jiangnan University
Phase 1 Recruiting
NCT03291444 2024-03-15
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Zhujiang Hospital
Phase 1 Recruiting
NCT05521802 2023-03-24
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Shanghai AbelZeta Ltd.
Phase 1/2 Recruiting
NCT05354375 2022-04-29
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
The Affiliated Hospital of Xuzhou Medical University
Phase 1 Recruiting
NCT05043571 2021-09-14
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
National University Hospital, Singapore
Phase 1 Recruiting
NCT05038696 2021-09-09
ALaCART
National University Hospital, Singapore
Phase 1 Recruiting
NCT04532203 2020-10-26
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting